最新ニュース ImmunityBio (NASDAQ:IBRX) 株価情報

ImmunityBio

ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: United states and Europe. Key revenue is generated from Europe.

News

Movers

AMKR

BILI

BRFS

IBRX

IRTC

ITCI

OLLI

RKLB

TALO

これらの中型株は先週最も楽観的なパフォーマンスを示しました。あなたのポートフォリオには入っていますか？Bilibili Inc.は（NASDAQ：BILI）は、先週「三國：謀定天下」の発売以降23.32%上昇しました。さらに、JPモルガン（JP Morgan）のアナリスト、ダニエル・チェン氏はBilibiliの株をニュートラル（中立評価）からオーバーウェイト（買い評価）に格上げし、21ドルの株価予測を発表しました。

中国配信大手ビリビリ　株価が23%の高騰

Biotech

Health Care

General

月曜日、米食品医薬品局（FDA）はAnktiva（N-803、またはnogapendekinアルファinbakicept-pmln）をツガダケ菌カルメット・ゲレン（BCG）と併用して、原発性非筋層浸潤性膀胱癌（NMIBC）と癌腫内局所性膀胱癌（CIS）に対して承認しました。 ；腺腫を伴う場合と伴わない場合があります。

FDAはImmunityBioの膀胱癌薬の承認を認め、株価が上昇

月曜日、米食品医薬品局（FDA）はAnktiva（N-803、またはnogapendekinアルファinbakicept-pmln）をツガダケ菌カルメット・ゲレン（BCG）と併用して、原発性非筋層浸潤性膀胱癌（NMIBC）と癌腫内局所性膀胱癌（CIS）に対して承認しました。

ImmunityBio Inc

Domino's Pizza CFO Says Expect Margin Growth To Be Lower In The First Half Of The Year Than The Second Half

WIIM

WeRide shares are trading higher after the company announced it received approval to launch its new GXR for its first fully unmanned commercial operations in Beijing.

WeRide Robotaxi GXR Receives Approval To Launch First Fully Unmanned Commercial Operations In Beijing

Nvidia Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) has been the poster child of the AI revolution, but cracks are showing as supplier delays and technical indicators <a href="https://www.benzinga.com/quote/NVDA/news">flash warning signs</a>. 
Analyst Beth Kindig, typically bullish on Nvidia, recently sounded the alarm after <a href="https://io-fund.com/semiconductors/supply-chain/nvidia-gb200-delays-mixed-signals-nvda-stock-analysis">scrutinizing supplier commentary</a>. 
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Key suppliers for Nvidia's GB200 NVL systems are not exactly inspiring confidence in Q1 and fiscal year guidance. Instead, a few have actually lowered guidance. Tomorrow, keep an eye on your inboxes as I break down the mixed signals that I'm hearing from Nvidia suppliers for the…
&mdash; Beth Kindig (@Beth_Kindig) <a href="https://twitter.com/Beth_Kindig/status/1893326435768496356?ref_src=twsrc%5Etfw">February 22, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
The takeaway? The GB200 rollout might not be as smooth as expected and NVDA stock could feel the heat.
<h2 class="wp-block-heading">Supplier Red Flags: Delays Mount</h2>
Super Micro Computer Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>), a key Nvidia partner, trimmed its fiscal 2025 revenue guide, citing Blackwell GPU delays. CEO Charles Liang had previously expected 30% of racks to use direct liquid cooling (DLC) by mid-2025. That target has now quietly slipped to early 2026. 
Worse, SMCI admitted they can't ship Blackwell NVL systems in volume for the March quarter—a red flag for Nvidia's near-term growth.
Vertiv Holdings Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VRT#NYSE">VRT</a>), another Nvidia ecosystem player, reported strong fourth quarter results but guided for softer first quarter growth, blaming &#8220;timing differences&#8221; in AI shipments. Meanwhile, PCIe 6.0 and PMIC suppliers, crucial for Blackwell systems, now expect volume deployments only in the back half of the year. 
Semtech's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMTC#NASDAQ">SMTC</a>) decision to pull guidance on active copper cabling further reinforces the narrative of a bumpy road.
Read Also: <a href="https://www.benzinga.com/25/02/43908370/amd-reshapes-strategy-plans-4-billion-data-center-asset-sale-while-doubling-down-on-gpus">AMD Reshapes Strategy, Plans $4 Billion Data Center Asset Sale While Doubling Down on GPUs</a>
<h2 class="wp-block-heading">NVDA Stock Technicals: Momentum Fades</h2>
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent022425&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="629" height="489" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/24081439/Screenshot-2025-02-24-at-6.44.28-PM.png" alt="" class="wp-image-795366" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/24081439/Screenshot-2025-02-24-at-6.44.28-PM.png 629w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/24081439/Screenshot-2025-02-24-at-6.44.28-PM-300x233.png 300w" sizes="(max-width: 629px) 100vw, 629px" /></a></figure>
<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent022425&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">Chart created using Benzinga Pro</a>
NVDA stock has cooled off year-to-date, down 2.83%, despite a stellar 69.93% gain over the past year. The stock is struggling near its 50-day moving average, a key technical level that often signals whether bullish momentum can continue or falter. 
Trading volumes have thinned and the relative strength index (RSI) is around 50, indicating fading buying pressure. If NVDA stock breaks below $110, it could trigger a deeper pullback toward the $100 psychological support—a level that aligns with Kindig's view of a potential &#8220;buying opportunity&#8221; if the stock dips further.
<h2 class="wp-block-heading">Q4 Earnings Catalyst Or Reality Check?</h2>
With <a href="https://www.benzinga.com/quote/NVDA/earnings">earnings on deck</a> (reports fourth quarter after market close on Wednesday), Nvidia faces a moment of truth. 
If management acknowledges the supplier delays, the stock could slip further. However, strength from Hopper and B200 systems might offset the near-term Blackwell hiccup. 
Investors should brace for volatility. Nvidia's AI dominance isn't in question, but the road ahead looks bumpier than bulls might like.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/equities/25/02/43905646/nvidia-set-for-clear-beat-and-raise-special-as-ai-demand-surges-says-dan-ives">Nvidia Set For &#8216;Clear Beat And Raise Special&#8217; As AI Demand Surges, Says Dan Ives</a></li>
</ul>

Analyst Color

Long Ideas

Technicals

Analyst Ratings

Tech

Trading Ideas

NVDA

SMCI

SMTC

Nvidia Stock Offers 'Buying Opportunity' Below $100 - Supplier Woes Suggest Caution, Says Analyst

AllianceBernstein Holding shares are trading higher after Equitable Holdings launched a $1.8 billion tender offer for a 4.7% stake in the company.

Needham analyst Ami Fadia reiterates Axsome Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>) with a Buy and maintains $153 price target.

Price Target

Reiteration

AXSM

Needham Reiterates Buy on Axsome Therapeutics, Maintains $153 Price Target

TSLA

Tesla shares are trading higher after the company announced it will deploy full self-driving (FSD) features in China.

J.P. Morgan dedicates balance sheet and adds co-lenders to provide private credit to clients
J.P. Morgan announced today at its 30th annual <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.jpmorgan.com%2Finvestment-banking%2Fdebt-capital-markets%23conferences&amp;esheet=54212050&amp;newsitemid=20250224176509&amp;lan=en-US&amp;anchor=Global+Leveraged+Finance+Conference&amp;index=1&amp;md5=d9a173b884864c4d1131a98380090129">Global Leveraged Finance Conference</a> a significant expansion to its private credit commitment. The firm is allocating $50 billion from its balance sheet, along with nearly $15 billion from multiple co-lenders. This strategic move is designed to extend the firm's direct lending capabilities and provide tailored private credit solutions to meet the evolving needs of clients.

Financing

J.P. Morgan Increases Direct Lending Commitment To $50B

Connexa Sports Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YYAI#NASDAQ">YYAI</a>) shares are <a href="https://www.benzinga.com/premarket">trading higher in premarket</a> on Monday after details emerged about a partnership with TikTok.
The sports equipment and technology provider launched a new initiative <a href="https://www.benzinga.com/pressreleases/25/02/g43909370/connexa-sports-technologies-inc-signs-content-creation-agreement-with-tiktok-for-the-middle-east-a">through its majority-owned subsidiary</a>, Yuanyu Enterprise Management Limited (YYEM). The company, with TikTok, will develop and distribute content aimed at the Middle East and North Africa (MENA).
The move is part of Connexa&#8217;s expansion into social networking applications and content creation.
The Multi-Channel Network (MCN) agency services agreement will have YYEM create content tailored for TikTok users in the MENA region. Genres will span sports, gaming and lifestyle.
Well-known Twitch personalities and other influencers will be responsible for producing live-streams and videos. 
This partnership seeks to capitalize on TikTok&#8217;s extensive reach in the region. As of July 2024, penetration rates surpass 120% in countries such as the United Arab Emirates and Saudi Arabia.
Also Read: <a href="https://www.benzinga.com/25/02/43880110/james-bond-franchise-shifts-hands-to-amazon-mgm-studios">James Bond&#8217;s New Era: Amazon MGM Studios Takes Creative Reins of Franchise</a>
This collaboration also aims to produce content like live-streams and voice chat rooms. The success of the agreement will hinge on the level of engagement from TikTok users and the conversion rates in the region. 
&#8220;This deal has the potential to create new revenue streams for YYAI, as well as marketing and other opportunities related to YYEM&#8217;s engagement with TikTok&#8217;s large and growing base of users and fans. Given the challenges TikTok is facing in the United States, we believe that partnering with TikTok in the MENA region presents a unique opportunity,&#8221; said YYAI Chairman Hongyu Zhou. 
&#8220;We expect to grow our social networking, influencer, and content creation business over the coming year and anticipate that our new social networking vertical will open further opportunities for YYAI.&#8221;
In 2024, Congress enacted a bipartisan law that prohibited TikTok, a decision <a href="https://www.benzinga.com/news/global/25/02/43604572/jd-vance-quarterbacking-tiktok-deal-will-his-venture-capital-experience-secure-a-win">subsequently affirmed by the U.S. Supreme Court</a>. 
However, an executive order from Trump postponed enforcement, leaving TikTok&#8217;s future in limbo as ByteDance scrambles to secure a buyer and complete the sale.
Price Action: YYAI shares are trading higher by 56.24% at $1.00 in premarket on Monday.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/02/43881721/coca-cola-warns-shortage-of-diverse-talent-could-harm-future-success">Coca-Cola Warns Shortage Of Diverse Talent Could Harm Business</a></li>
</ul>
Image: Shutterstock

Entertainment

Social Media

Sports

Connexa Sports Technologies Inc. - Common Stock

YYAI

TikTok Collaboration Powers Connexa's New MENA Strategy

Earnings

YSXT

YSX Tech. Co. Six Months Ended September 30, 2024 EPS $0.09 Vs $0.11 YoY; Revenue $34.09M Vs $26.5M YoY

United Airlines Holdings's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UAL#NYSE">UAL</a>) short percent of float has fallen 18.24% since its last report. The company recently reported that it has 14.81 million shares sold short, which is 5.11% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.01 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>United Airlines Holdings Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1740404726_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for United Airlines Holdings has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing United Airlines Holdings's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, United Airlines Holdings's peer group average for short interest as a percentage of float is 8.32%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

How Do Investors Really Feel About United Airlines Holdings?

Starwood Prop Trust's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STWD#NYSE">STWD</a>) short percent of float has fallen 3.01% since its last report. The company recently reported that it has 12.35 million shares sold short, which is 3.87% of all regular shares that are available for trading. Based on its trading volume, it would take traders 6.64 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Starwood Prop Trust Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1740404721_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Starwood Prop Trust has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Starwood Prop Trust's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Starwood Prop Trust's peer group average for short interest as a percentage of float is 7.09%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

STWD

Looking Into Starwood Prop Trust's Recent Short Interest

Universe Pharmaceuticals's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UPC#NYSE">UPC</a>) short percent of float has fallen 99.26% since its last report. The company recently reported that it has 5 thousand shares sold short, which is 0.06% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.0 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Universe Pharmaceuticals Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1740404716_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Universe Pharmaceuticals has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Universe Pharmaceuticals's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Universe Pharmaceuticals's peer group average for short interest as a percentage of float is 7.99%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Looking Into Universe Pharmaceuticals's Recent Short Interest

TWLO

Twilio shares are trading higher after JP Morgan upgraded the stock from Equal-Weight to Overweight and raised its price target from $144 to $160.

KPTI

Karyopharm Announces 1-for-15 Reverse Stock Split, Effective February 25, 2025

SMMT

Summit Therapeutics shares are trading higher after the company reported better-than-expected Q4 adjusted EPS results. Additionally, the company announced it will partner with Pfizer through a clinical trial to advance cancer treatments with novel antibody combinations.

Contracts

UBER

Domino's Pizza CEO Says Extended Exclusivity Arrangement With Uber Until May 1, Begun Negotiations With Additional Aggregator Partners

Vivos announces immediate expansion of its new alliance model into two additional Colorado locations as initial reports show sleep apnea patients prefer Vivos CARE treatment for OSA nearly 2 to 1 over CPAP
Vivos seeking additional alliances or acquisitions of sleep medicine practices to fuel national expansion objectives
LITTLETON, Colo., Feb. 24, 2025 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=Wxen1KDOWNGP7PNeeQeGiVLp8wsDTN4SbC2mazqhcL38BcSZ8cKP8Q5b5dWrnWLggJKGwfyhYsqYbQOVpUkeREIrIIElerogvDu0IAFReRU=">Vivos Therapeutics, Inc.</a> ("Vivos" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VVOS#NASDAQ">VVOS</a>), a leader in novel, non-invasive obstructive sleep apnea (OSA) treatments, today announced several significant milestone achievements in its efforts to extend its <a href="https://www.globenewswire.com/Tracker?data=bPVYenN2C1NXTt4_aH2uV2_jtFtK0w2uH7ohABHp_YEelomXoBDo8vpWSjL5UzPA_-mlb7AVLS1N6bMi86-xoZlcPw9PD-DhNdJV68InxTM=">FDA cleared Vivos CARE</a> treatment for OSA to as many patients as possible.
Vivos also announced expansion of its strategic marketing and distribution alliance with Rebis Health Holdings (Rebis Health) launched last June into two additional facilities in the greater Denver market, along with plans to extend its marketing and distribution model throughout the United States with potential additional sleep center affiliations and acquisitions.

VVOS

Vivos Therapeutics Announces Expansion Of Alliance Model To Two More Colorado Locations As Sleep Apnea Patients Prefer Vivos CARE Nearly 2:1 Over CPAP; Seeks Further Alliances Or Acquisitions For National Growth

Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) is poised to reach $180,000 by the end of 2025, according to a prediction from Grok 3, an AI developed by xAI, driven by growing institutional adoption and <a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43889897/bitcoin-strategic-reserve-with-1-million-btc-could-offset-21-trillion-national-debt">potential U.S. strategic reserve status</a>.
What Happened: The analysis, prompted by Strategy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) executive chairman Michael Saylor's <a href="https://x.com/saylor/status/1893389452908601704">query</a> on X on Sunday about the best crypto asset, positions Bitcoin as the dominant cryptocurrency in a $3.23 trillion market.
Grok outlined several factors supporting Bitcoin's continued dominance, including its scarcity, institutional backing, and potential inclusion in the U.S. strategic reserves. 
"Bitcoin is the best crypto asset in 2025," the AI noted, citing its status as "digital gold" and its fixed supply of 21 million coins.
The analysis pointed to increasing adoption among institutions as a major catalyst for Bitcoin's price growth. 
Companies such as Strategy have continued accumulating Bitcoin, reinforcing confidence in the asset.
Additionally, Grok referenced growing speculation about Bitcoin&#8217;s role in national reserves, stating that its "potential U.S. adoption as a <a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43772661/us-could-sell-its-gold-to-set-up-potential-bitcoin-reserve-says-bernstein-will-it-ignite-a-global-race-to-buy-btc">strategic reserve</a>" could further fuel demand.
Political factors also play a role in Bitcoin's prospects. 
Also Read: <a href="https://www.benzinga.com/25/02/43901027/bybit-offers-140m-bounty-in-wake-of-14b-eth-hack-investigation-focuses-on-safe">Bybit Offers $140M Bounty In Wake of $1.4B ETH Hack, Investigation Focuses On Safe</a>
Grok highlighted U.S. President Donald Trump's recent pro-crypto stance, which has led to speculation that future policies may favor Bitcoin's broader adoption. 
The AI described this political shift as a "bullish milestone" that could drive further institutional engagement.
Bitcoin's price stood at approximately $95,594 at the time of publication. 
Grok noted that despite short-term fluctuations, Bitcoin's long-term trajectory remains strong. 
"Its resilience through market cycles and recent political endorsements boost its position," the AI explained.
What&#8217;s Next: Bitcoin currently holds a 61.1% dominance over the $3.23 trillion cryptocurrency market.
Compared to alternatives like Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) ($329 billion market cap) and Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>) ($84 billion market cap), Bitcoin continues to lead as the preferred choice for long-term investment.
Grok's forecast aligns with bullish predictions from other market analysts, with firms like VanEck projecting a peak in the crypto bull market <a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43889897/bitcoin-strategic-reserve-with-1-million-btc-could-offset-21-trillion-national-debt#:~:text=VanEck%20proposes%20a%20strategic%20bitcoin,of%20a%20federal%20Bitcoin%20reserve.">by early 2025</a>.
The AI emphasized that Bitcoin's appeal as a hedge against inflation and store of value remains its strongest asset. 
"If Bitcoin's adoption continues to grow, the projected price increase could become a reality," it stated.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43890188/bybit-founder-says-14b-eth-hack-may-stem-from-safe-wallet-compromise">Bybit Founder Says $1.4B ETH Hack May Stem From Safe Wallet Compromise</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$ETH

$SOL

MSTR

Grok 3 Predicts Bitcoin Dominance In 2025, Projects $180,000 Price Target

<a href="https://www.wsj.com/business/hospitality/starbucks-to-lay-off-more-than-1-000-workers-0d0be043?mod=latest_headlines" title="https://www.wsj.com/business/hospitality/starbucks-to-lay-off-more-than-1-000-workers-0d0be043?mod=latest_headlines">https://www.wsj.com/business/hospitality/starbucks-to-lay-off-more-than-1-000-workers-0d0be043?mod=latest_headlines</a>

Management

SBUX

'Starbucks To Lay Off More Than 1,000 Workers; New CEO Brian Niccol Says Corporate Cuts Needed As Part Of Turnaround' - WSJ

Press Releases

ImmunityBio, Inc. Announces Proposed Public Offering of Common Stock

ImmunityBio, Inc. Announces Pricing of Public Offering of Common Stock

D. Boral Capital Served as Co-Manager to ImmunityBio, Inc. (Nasdaq: IBRX) in connection with its $100.0 Million Underwritten Public Offering

ImmunityBio Announces Permanent J-code (J9028) for ANKTIVA® Is Now Effective

ImmunityBio Provides Regulatory Update on Anticipated FDA Submissions in 2025 Following Meeting with the Agency

ImmunityBio Provides Regulatory Update on Global Submission for ANKTIVA + BCG in BCG Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in situ in Europe and United Kingdom

ImmunityBio Announces European Medicines Agency Acceptance of Marketing Authorization Application for ANKTIVA® for the Treatment of Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ

ImmunityBio Announces Collaboration with BeiGene on Confirmatory Phase 3 Trial of ANKTIVA® and PD-1 Checkpoint Inhibitor Combination in Non-Small Cell Lung Cancer

ImmunityBio Announces UK Medicines and Healthcare Products Regulatory Agency Accepted Marketing Authorization Application for ANKTIVA® for the Treatment of Patients with BCG-unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ

FDA Authorizes ImmunityBio to Provide Recombinant BCG (rBCG) to Urologists to Address TICE® BCG Shortage

ACADIA Pharmaceuticals Inc. - Common Stock

ACADIA Pharmaceuticals

Agios Pharmaceuticals, Inc. - Common Stock

Agios Pharmaceuticals

Apogee Therapeutics

Apellis Pharmaceuticals, Inc. - Common Stock

Apellis Pharmaceuticals

Arrowhead Pharmaceuticals, Inc. - Common Stock

Arrowhead Pharma

Beam Therapeutics

CG Oncology

Centessa Pharmaceuticals plc - American Depositary Shares

Centessa Pharmaceuticals

Catalyst Pharmaceuticals, Inc. - Common Stock

Catalyst Pharmaceuticals

Denali Therapeutics

Amicus Therapeutics

IDEAYA Biosciences

Janux Therapeutics

Kymera Therapeutics

Mesoblast Limited - American Depositary Shares

Mesoblast

Mirum Pharmaceuticals, Inc. - common stock

Mirum Pharmaceuticals

MoonLake Immunotherapeutics - Class A Ordinary Shares

MoonLake

Metsera

NewAmsterdam Pharma Company N.V. - Ordinary Shares

NewAmsterdam Pharma

Protagonist Therapeutics, Inc. - Common Stock

Protagonist Therapeutics

Soleno Therapeutics

Travere Therapeutics, Inc. - Common Stock

Travere Therapeutics

Twist Bioscience Corporation - Common Stock

Twist Bioscience

Vericel

Veracyte

D. Boral Capital

BTIG

EF Hutton

Piper Sandler

Jefferies

これらの中型株は先週最も楽観的なパフォーマンスを示しました。あなたのポートフォリオには入っていますか？
<ol>
<li>Bilibili Inc.は（NASDAQ：<a class="ticker" href="https://www.benzinga.com/stock/BILI#NASDAQ">BILI</a>）は、先週「三國：謀定天下」の発売以降23.32%上昇しました。さらに、JPモルガン（JP Morgan）のアナリスト、ダニエル・チェン氏はBilibiliの株をニュートラル（中立評価）からオーバーウェイト（買い評価）に格上げし、<a href="https://www.benzinga.com//node/39418621" target="_blank" rel="noreferrer noopener">21ドルの株価予測を発表しました</a>。</li>
<li>ImmunityBio, Inc.は（NASDAQ：<a class="ticker" href="https://www.benzinga.com/stock/IBRX#NASDAQ">IBRX</a>）の株は、複数の州でのANKTIVAの保険適用の発表後、22.36%上昇しました。<a href="https://www.benzinga.com//node/39417764" target="_blank" rel="noreferrer noopener">最初の商用用量が投与されました</a>。</li>
<li>Sasol Ltd.は（NYSE：<a class="ticker" href="https://www.benzinga.com/stock/SSL#NYSE">SSL</a>）の株は、この会社が裁判所の判決を受け、TotalEnergies SE（NYSE：<a class="ticker" href="https://www.benzinga.com/stock/TTE#NYSE">TTE</a>）マーケティングの訴えを認められたことを発表した後、20.89%上昇しました。また、同社は損害に対して39億ランド（約389億円）と、利息に対して約23億ランド（約230億円）を受領しました。<a href="https://www.benzinga.com//node/39412202" target="_blank" rel="noreferrer noopener">and approximately R2.3B in interest</a>。</li>
<li>Ollie&#8217;s Bargain Outlet Holdings Inc（NASDAQ：<a class="ticker" href="https://www.benzinga.com/stock/OLLI#NASDAQ">OLLI</a>）の株は、先週JPモルガンが株をニュートラルからオーバーウェイトに格上げした後、15.25%上昇しました。</li>
<li>Intra-Cellular Therapies Inc.は（NASDAQ：<a class="ticker" href="https://www.benzinga.com/stock/ITCI#NASDAQ">ITCI</a>）の株は、この会社が主要な抗うつ症状を持つ患者を対象として、補助療法としてLumateperoneを評価する第2相3試験のトップライン結果を発表した後、13.18%上昇しました。<a href="https://www.benzinga.com//node/39382029" target="_blank" rel="noreferrer noopener">meeting primary and key secondary endpoints</a>。</li>
<li>Amkor Technology, Inc.は（NASDAQ：<a class="ticker" href="https://www.benzinga.com/stock/AMKR#NASDAQ">AMKR</a>）の株は、チップ株の強さ全体で12.06%上昇しました。また、B.ライリー証券のアナリストは、<a href="https://www.benzinga.com/quote/AMKR/analyst-ratings">アナリストレーティング</a>を45ドルから50ドルに株価予測を引き上げました。</li>
<li>IRhythm Technologies, Inc.は（NASDAQ：<a class="ticker" href="https://www.benzinga.com/stock/IRTC#NASDAQ">IRTC</a>）の株は、製造自動化の初期フェーズを発表後、11.53%上昇しました。</li>
<li>Rocket Lab USA, Inc.は（NASDAQ：<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>）の株は、<a href="https://www.benzinga.com//node/39429411" target="_blank" rel="noreferrer noopener">東京の日本の会社シンペクティブとの10回の打ち上げ契約を締結した後、11.32%上昇しました。</a></li>
<li>Bread Financial Holdings, Inc.（NYSE：<a class="ticker" href="https://www.benzinga.com/stock/BFH#NYSE">BFH</a>）の株は、Evercore ISI Groupが株をアンダーパフォームからインラインに格上げし、その価格ターゲットを42ドルから45ドルに引き上げた後、10.81%上昇しました。また、RBCキャピタルは株に対してセクターパフォームの格付けを維持し、その <a href="https://www.benzinga.com/quote/BFH/analyst-ratings" target="_blank" rel="noreferrer noopener">45ドル</a>まで<a href="https://www.benzinga.com/quote/BFH/analyst-ratings" target="_blank" rel="noreferrer noopener">38ドル</a>。</li>
<li>BRF S.A.は（NYSE：<a class="ticker" href="https://www.benzinga.com/stock/BRFS#NYSE">BRFS</a>）の株は、10.69%上昇しました。</li>
</ol>
ウィキメディア・コモンズより
その他の記事: <a href="https://www.benzinga.com/news/24/06/39447506/gamestop-and-first-solar-were-among-the-10-biggest-large-cap-losers-last-week-june-16-june-22-are-th">先週の大型株の10大下落銘柄（6月16日～6月22日）</a>

月曜日、米食品医薬品局（FDA）はAnktiva（N-803、またはnogapendekinアルファinbakicept-pmln）をツガダケ菌カルメット・ゲレン（BCG）と併用して、原発性非筋層浸潤性膀胱癌（NMIBC）と癌腫内局所性膀胱癌（CIS）に対して承認しました。 ；<a href="https://www.benzinga.com/pressreleases/24/04/b38368486/immunitybio-announces-fda-approval-of-anktiva-first-in-class-il-15-receptor-agonist-for-bcg-unresp" target="_blank" rel="noopener noreferrer">腺腫を伴う場合と伴わない場合があります</a>。
この薬は、結核の治療に使われているBCGワクチンと組み合わされています。また、特定の膀胱癌の形態の治療法としても使用されています。
昨年5月に、FDAはAnktivaとBCGの治療法について、米国食品医薬品局の第三者<a href="https://www.benzinga.com/general/biotech/23/05/32341596/stock-loses-50-in-one-trading-session-why-are-immunitybio-shares-tanking-today" target="_blank" rel="noopener noreferrer">契約製造企業</a>の検査中に見つかった欠陥を理由に、一次審査通過に関する完全回答書を発行しました。
「FDAによるANKTIVAの承認は、私たちがチェックポイント阻害剤を超える次世代の免疫療法を開始することを示しています」と、ImmunityBioのエグゼクティブチェアマンでグローバルチーフサイエンティフィック・アンド・メディカル・オフィサーのパトリックスンションク氏は述べています。 
同社によると、AnktivaはCISを伴うNMIBCの最初のIL-15アゴニスト免疫療法であり、FDAは、完全反応（CR）と完全反応継続期間（DOR）の安全性と有効性の結果に基づく、相当な成果が出るとして、同薬に対して早期開発薬指定と承認を付与しました。 
CRの率は、77人の患者のうちの評価可能な患者数で62%で、その信頼区間の上限は73%です。 
2023年11月時点の完全反応の期間は、最大で47ヶ月以上で、現在も継続中です。 
同社は、ANKTIVAとBCGとの間に見られた完全反応の期間の長期化は、IBCどくの専門家のパネルが提案する意義のある臨床結果の基準を上回っているとしています。
この反応の持続期間は今も継続中であり、したがって反応の最終中央値の期間は確定していません。CRが確認された患者のうち、58%がDORが12ヶ月以上であり、40%がDORが24ヶ月以上です。
Anktivaは、2024年5月の中旬までには米国で利用可能になる予定です。
株価動向：IBRX株は、最終確認時点の火曜日の午後5.17ドルで4.65%上昇しています。

月曜日、米食品医薬品局（FDA）はAnktiva（N-803、またはnogapendekinアルファinbakicept-pmln）をツガダケ菌カルメット・ゲレン（BCG）と併用して、原発性非筋層浸潤性膀胱癌（NMIBC）と癌腫内局所性膀胱癌（CIS）に対して承認しました。 ；<a href="https://www.benzinga.com/pressreleases/24/04/b38368486/immunitybio-announces-fda-approval-of-anktiva-first-in-class-il-15-receptor-agonist-for-bcg-unresp" target="_blank" rel="noopener noreferrer">腺腫を伴う場合と伴わない場合があります</a>。
この薬は、結核の治療に使われているBCGワクチンと組み合わされています。また、特定の膀胱癌の形態の治療法としても使用されています。
昨年5月に、FDAはAnktivaとBCGの治療法について、米国食品医薬品局の第三者<a href="https://www.benzinga.com/general/biotech/23/05/32341596/stock-loses-50-in-one-trading-session-why-are-immunitybio-shares-tanking-today" target="_blank" rel="noopener noreferrer">契約製造企業</a>の検査中に見つかった欠陥を理由に、一次審査通過に関する完全回答書を発行しました。
「FDAによるANKTIVAの承認は、私たちがチェックポイント阻害剤を超える次世代の免疫療法を開始することを示しています」と、ImmunityBioのエグゼクティブチェアマンでグローバルチーフサイエンティフィック・アンド・メディカル・オフィサーのパトリックスンションク氏は述べた。
同社によると、AnktivaはCISを伴うNMIBCの最初のIL-15アゴニスト免疫療法であり、FDAは、完全反応（CR）と完全反応継続期間（DOR）の安全性と有効性の結果に基づく、相当な成果が出るとして、同薬に対して早期開発薬指定と承認を付与しました。
CRの率は、77人の患者のうちの評価可能な患者数で62%で、その信頼区間の上限は73%です。
2023年11月時点の完全反応の期間は、最大で47ヶ月以上で、現在も継続中です。
同社は、ANKTIVAとBCGとの間に見られた完全反応の期間の長期化は、IBCどくの専門家のパネルが提案する意義のある臨床結果の基準を上回っているとしています。
この反応の持続期間は今も継続中であり、したがって反応の最終中央値の期間は確定していません。CRが確認された患者のうち、58%がDORが12ヶ月以上であり、40%がDORが24ヶ月以上です。
Anktivaは、2024年5月の中旬までには米国で利用可能になる予定です。
株価動向：IBRX株は、最終確認時点の火曜日の午後5.17ドルで4.65%上昇しています。

Comments

ImmunityBio

ニュース

最新ニュース ImmunityBio (NASDAQ:IBRX) 株価情報

月曜日, 6 24, 2024

金曜日, 4 26, 2024

火曜日, 4 23, 2024

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル